Nuformix PLC
25 August 2026
25 August 2026
Nuformix plc
("Nuformix" or the "Company")
Appointment of Chairman
Nuformix plc (LSE), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce the appointment of Tim Metcalfe as Non-Executive Chairman and a Director of the Company with effect from 1 September 2026.
Julian Gilbert, the Company's current Non-Executive Chairman, has decided to step down from the Board on 31 August 2026 for personal reasons, but he will remain available to the Company in a consultancy capacity, providing continuity and access to his considerable sector knowledge and experience.
Tim is a highly experienced corporate financier and company adviser, having spent over 30 years in a variety of senior City and corporate roles. He has held senior positions at Robert Fleming, Rothschild, Westhouse Securities, Northland Capital Partners and he was Joint CEO of Zeus Capital, prior to co-founding IFC Advisory, an investor relations and financial PR adviser, in 2015. During his career, Tim has had a particular focus on advising companies on strategy, M&A, capital markets and regulatory matters.
In addition to his role as Managing Director of IFC Advisory, Tim is Senior Independent Non-Executive Director of The Investment Company plc, an investment trust listed on the Main Market of the London Stock Exchange, and Non-Executive Chairman of Equipmake Holdings plc, which is listed on Aquis. He is also a director of a number of private companies.
Dr Julian Gilbert, outgoing Non-Executive Chairman of Nuformix, commented: "I am very pleased that Tim has agreed to become Chairman of Nuformix. I have worked closely with Tim and believe his extensive corporate, capital markets and strategic experience will be highly valuable to the Company as it seeks to maximise the value of its NXP002 programme and considers the opportunities available to it.
"I would like to thank our shareholders and the Nuformix team for their support during my time as Chairman and I look forward to continuing to support the Company in a consultancy capacity."
Tim Metcalfe, incoming Non-Executive Chairman of Nuformix, commented: "I am delighted to be joining Nuformix as its new Chairman. I look forward to working closely with Dan and the wider team, with a particular focus on creating value for shareholders through the Company's NXP002 programme, ongoing partnering discussions and the consideration of broader strategic opportunities that can enhance the Company's prospects and deliver long-term value."
Further information
In accordance with UKLR 6.4.8R, Timothy ("Tim") Mark Metcalfe currently holds, or has held during the five years preceding the date of this announcement, the following directorships of publicly quoted companies:
Current: Equipmake Holdings plc; The Investment Company plc
Former: Spiritus Mundi plc
There is no further information required to be disclosed pursuant to UKLR 6.4.8R.
Enquiries:
|
Nuformix plc |
|
|
Dr Julian Gilbert, Non-Executive Chairman Dr Dan Gooding, Executive Director Tim Metcalfe, incoming Non-Executive Chairman
|
Via IFC Advisory |
|
CMC Markets |
|
|
Douglas Crippen |
+44 (0) 20 3003 8632 |
|
IFC Advisory Limited |
|
|
Graham Herring Zach Cohen |
+44 (0) 20 3934 6632 nuformix@investor-focus.co.uk |
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.
For more information, please visit www.nuformix.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.